Voyager Therapeutics Management
Management criteria checks 2/4
Voyager Therapeutics' CEO is Al Sandrock, appointed in Mar 2022, has a tenure of 3.67 years. total yearly compensation is $3.38M, comprised of 19.3% salary and 80.7% bonuses, including company stock and options. directly owns 0.24% of the company’s shares, worth $627.00K. The average tenure of the management team and the board of directors is 3.2 years and 4.5 years respectively.
Key information
Al Sandrock
Chief executive officer
US$3.4m
Total compensation
| CEO salary percentage | 19.31% |
| CEO tenure | 3.7yrs |
| CEO ownership | 0.2% |
| Management average tenure | 3.2yrs |
| Board average tenure | 4.5yrs |
Recent management updates
Recent updates
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Held Back By Insufficient Growth Even After Shares Climb 27%
Sep 25
Voyager Therapeutics: Navigating AAV Headwinds And A Long Road For VY7523 (Downgrade)
Jun 06It's Unlikely That The CEO Of Voyager Therapeutics, Inc. (NASDAQ:VYGR) Will See A Huge Pay Rise This Year
May 27Positive Sentiment Still Eludes Voyager Therapeutics, Inc. (NASDAQ:VYGR) Following 27% Share Price Slump
Feb 25Voyager: Crossing The Blood-Brain Barrier, Competitors, And Investment Relevance
Jan 30
Developing Tau-Targeting Therapies Will Open Doors But May Encounter Setbacks
Strong partnerships and collaborations are expected to enhance revenue and earnings through milestone payments and shared R&D efforts.Voyager Therapeutics' Tracer Platform Targets CNS Market: Here's Why I'm Neutral
Nov 18Improved Revenues Required Before Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock's 27% Jump Looks Justified
Oct 17Voyager Therapeutics: CNS Player In Early Stages Of A Turnaround
Aug 26Earnings Beat: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Aug 09Lacklustre Performance Is Driving Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Low P/S
Aug 08Voyager: Alzheimer's Clinical Trial Start (VY-TAU01) Strengthens Investment Thesis
Jun 05There's No Escaping Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Muted Revenues Despite A 28% Share Price Rise
Mar 15Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier
Mar 08What Does The Future Hold For Voyager Therapeutics, Inc. (NASDAQ:VYGR)? These Analysts Have Been Cutting Their Estimates
Mar 04Voyager Therapeutics, Inc. (NASDAQ:VYGR) Surges 45% Yet Its Low P/S Is No Reason For Excitement
Jan 04Voyager stock rises as Pfizer opts to use AAV capsid for neurologic disease target
Oct 04Voyager Therapeutics hires new finance chief
Sep 07Voyager Therapeutics GAAP EPS of -$0.50 misses by $0.02
Aug 04CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | n/a | n/a | -US$108m |
| Mar 31 2025 | n/a | n/a | -US$85m |
| Dec 31 2024 | US$3m | US$652k | -US$65m |
| Sep 30 2024 | n/a | n/a | US$26m |
| Jun 30 2024 | n/a | n/a | US$9m |
| Mar 31 2024 | n/a | n/a | -US$3m |
| Dec 31 2023 | US$3m | US$624k | US$132m |
| Sep 30 2023 | n/a | n/a | US$52m |
| Jun 30 2023 | n/a | n/a | US$96m |
| Mar 31 2023 | n/a | n/a | US$99m |
| Dec 31 2022 | US$7m | US$525k | -US$46m |
Compensation vs Market: Al's total compensation ($USD3.38M) is above average for companies of similar size in the US market ($USD1.49M).
Compensation vs Earnings: Al's compensation has increased whilst the company is unprofitable.
CEO
Al Sandrock (67 yo)
Dr. Alfred W. Sandrock Jr., also known as Al, M.D., Ph D., is Director of FORUM Pharmaceuticals Inc. from May 2012. Dr. Sandrock joined the FORUM Pharmaceuticals Inc. in May 2012.Dr. Sandrock is President...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.7yrs | US$3.38m | 0.24% $ 627.0k | |
| CFO, Principal Financial Officer & Principal Accounting Officer | 1.3yrs | US$2.12m | 0.034% $ 88.7k | |
| Chief Medical Officer | 1.7yrs | US$3.08m | 0.011% $ 27.6k | |
| Founder | no data | no data | no data | |
| Founder | no data | no data | no data | |
| Chief Business Officer & COO | no data | US$1.38m | 0.31% $ 792.2k | |
| Chief Scientific Officer | 3.2yrs | no data | 0.22% $ 577.8k | |
| Chief Corporate Affairs Officer & Chief of Staff to the CEO | 3.8yrs | no data | no data |
Experienced Management: VYGR's management team is considered experienced (3.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.8yrs | US$3.38m | 0.24% $ 627.0k | |
| Independent Director | 11.8yrs | US$210.00k | 0.14% $ 357.7k | |
| Independent Director | 2.5yrs | US$191.39k | 0% $ 0 | |
| Independent Director | 8.8yrs | US$195.00k | 0.039% $ 101.8k | |
| Independent Director | 10.2yrs | US$202.00k | 0% $ 0 | |
| Independent Chairman of the Board | 10.3yrs | US$227.50k | 0.056% $ 146.2k | |
| Independent Director | 3.3yrs | US$197.00k | 0% $ 0 | |
| Director | 2.8yrs | US$189.00k | 0.0053% $ 13.6k | |
| Independent Director | 2.8yrs | US$192.44k | 0% $ 0 | |
| Independent Director | 5.2yrs | US$201.50k | 0.18% $ 474.9k |
Experienced Board: VYGR's board of directors are considered experienced (4.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/02 23:45 |
| End of Day Share Price | 2025/10/31 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Voyager Therapeutics, Inc. is covered by 26 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Jack Allen | Baird |
| Aydin Huseynov | Benchmark Company |